Treating ankle cartilage damage without surgery

A scan confirms cartilage damage on the talus. The ankle has been painful since a sprain — or longer — and rest, physiotherapy, and anti-inflammatory medication have not resolved it. The next question is whether surgery is the only realistic path forward. For a defined group of patients with focal talar osteochondral lesions, it may not be.

ChondroFiller injection is an ultrasound-guided, outpatient collagen scaffold procedure — no theatre, no general anaesthetic, no arthroscopic port. A highly viscous, acellular Type I collagen gel is placed precisely into the cartilage defect under image guidance, where it polymerises in situ and creates a matrix that recruits the patient's own repair cells. The transition from a surgically implanted device to an injectable form represents a meaningful shift in how early and focal cartilage lesions can be managed.

Talar osteochondral lesions — areas where the cartilage surface and underlying subchondral bone of the talus have been disrupted — typically cause deep ankle pain, stiffness, and intermittent catching or locking, most often in active adults following ankle trauma. Because articular cartilage is avascular and aneural, its capacity for self-repair is inherently limited, which is why untreated lesions tend to progress rather than resolve.

What follows covers the biological mechanism, the available clinical evidence (and where ankle-specific data currently sits relative to other joints), and the patient characteristics that make someone a reasonable candidate for assessment.

How the injectable collagen scaffold works

Unlike a hyaluronic acid injection, which lubricates the joint without attempting to rebuild tissue, or a cell therapy such as ACI or MACI, which introduces laboratory-cultured chondrocytes, ChondroFiller is an acellular scaffold — no cells are injected at any point. The device is CE-marked as a Class III medical device and contains only murine-derived Type I collagen formulated to a high viscosity.

Once placed into the defect under ultrasound guidance as an outpatient procedure, the gel polymerises in situ — it sets within the cartilage void and forms a stable three-dimensional matrix. This matrix then acts chemotactically: it emits signals that draw the body's own progenitor cells out of the surrounding tissue and into the scaffold. The process is sometimes called matrix-induced chondrogenesis, which in plain terms means the scaffold does the recruiting so the patient's own cells do the repair work.

An ex vivo osteochondral study published in 2025 quantified this response, recording a 2.4-fold increase in DNA content within the scaffold by day 14 — direct laboratory evidence that host cells are actively migrating and proliferating inside the matrix.

One clinical implication follows from the gel's initial properties. A 2024 biomechanical study found that the collagen matrix is not immediately stable under full joint loading, which means early weight-bearing should be avoided until the defect is stably filled. For patients, this translates to a defined period of relative rest after the injection — the timeline for which is discussed at assessment — before a gradual return to normal activity.

What the clinical evidence shows — and where it currently stands for the ankle

Across four published knee studies, ChondroFiller produces IKDC score improvements of approximately 30 points — well above the minimum clinically important difference of 16.7 points. The Jerosch et al. PMCF cohort demonstrated a mean gain of 32.4 points sustained at three-year follow-up, with a mean IKDC score reaching 80. These are not solely symptomatic gains: MOCART scores of 81.6 to 84.3 across the knee series confirm structural cartilage repair on MRI — progressive defect fill and integration with native tissue. A randomised multicentre study of 13 ChondroFiller patients reported significant IKDC improvements at 3, 6, and 12 months (p<0.05) with no adverse events recorded.

The evidence extends beyond the knee. A 2025 wrist study (n=25) applied the scaffold to chondral defects following distal radius fractures, finding significantly better cartilage quality at follow-up arthroscopy — median Outerbridge grade 1.5 versus 3 in controls (P=0.006) and ICRS grade 1 versus 3 (P=0.002). In a hip cohort of 26 patients followed for up to five years, 17 of 21 evaluable patients achieved good or excellent outcomes. The important caveat from that cohort: patients with pre-existing osteoarthritis (Tönnis grade 2–3) fared poorly. That patient-selection signal — early and focal lesions respond; advanced joint degeneration does not — is a lesson that almost certainly carries over to ankle assessment.

No peer-reviewed clinical study has yet reported ChondroFiller injection specifically for talar osteochondral lesions. The ankle case rests on extrapolation from the multi-joint dataset above, underpinned by the biological plausibility of matrix-induced chondrogenesis in any hyaline cartilage environment. Consistent results across structurally diverse joints — knee, hip, small hand joints — lend that extrapolation reasonable weight, but it remains extrapolation, and patients considering this pathway for a talar lesion should be assessed with that evidence context clearly in view.

The ankle joint and why talar lesions are difficult to treat

Talar cartilage is typically 1–2 mm thick and, like cartilage throughout the body, has no blood supply of its own. Without vascular access, it cannot mount a meaningful repair response: a significant chondral injury in the ankle rarely heals spontaneously. Osteochondral lesions of the talus most often follow ankle sprain or direct trauma, though repetitive loading — common in running sports — can produce the same picture over time. Patients typically present with persistent deep ankle pain, swelling, and mechanical symptoms such as catching or locking.

When conservative management fails, the surgical options each carry meaningful burdens. Microfracture — historically first-line for lesions under 1.5 cm² — penetrates the subchondral bone to stimulate marrow cells, but produces fibrocartilage rather than hyaline-like repair tissue. Evidence across joint types shows this fibrocartilage tends to deteriorate at two to three years, and the technique's declining role in modern practice reflects that. For larger or recurrent lesions, autologous bone graft with a periosteal patch requires medial malleolar osteotomy — a deliberate cut through the ankle bone to gain access to the talar dome — with general anaesthesia, hardware fixation, and prolonged rehabilitation. A published series of 30 patients recorded AOFAS scores rising from 40.6 to 95.13 with this approach, illustrating both its efficacy and its procedural scale.

The ankle has nonetheless shown clear tolerance for injectable regenerative approaches. In a study of 42 patients receiving hyaluronic acid plus extracorporeal shockwave therapy following microfracture, AOFAS scores improved from 67.78 to 93.54 and VAS pain fell from 7.16 to 2.11. Intraosseous PRP injection for talar-region osteochondral lesions has also been reported. These precedents establish that the ankle accepts injectable biologics well — a clinically relevant foundation when evaluating a scaffold-based injection pathway for suitable focal lesions.

Who is a suitable candidate for ChondroFiller ankle injection

Focal and symptomatic is the starting point: the injection pathway suits discrete talar cartilage defects — structurally, those graded ICRS or Outerbridge II to III (partial- to near-full-thickness cartilage loss within a defined area, as opposed to diffuse joint-surface wear). Patients at these grades retain enough surrounding cartilage architecture for the scaffold to seat and for host cells to migrate inward. Grade IV through-and-through lesions are a more complex picture; suitability depends on the broader joint state and lesion geometry.

Defect size is a second filter. The collagen scaffold is designed for focal lesions up to approximately 3 cm², with the formulation applicable up to around 6 cm² — a wider range than microfracture's traditional upper limit. Very large, multi-focal, or combined osteochondral defects with significant bone involvement may need a different restorative strategy.

The typical referral is a younger, active patient — often post-ankle sprain or post-trauma — who has completed structured physiotherapy, activity modification, and possibly prior injection support without satisfactory relief, and who wants to avoid or postpone arthroscopic surgery. Age alone is not a formal cut-off; the health of the surrounding cartilage and the focal rather than diffuse character of the damage matter considerably more. Where ankle osteoarthritis is generalised rather than focal, the injectable scaffold pathway is not appropriate — the patient-selection principle the multi-joint evidence establishes applies directly here, without needing to re-examine those datasets.

Because symptoms and imaging findings do not always map cleanly onto these criteria, a specialist assessment — including weight-bearing X-ray and MRI — is the reliable way to determine whether a specific talar lesion falls within the scope of this approach.

What the outpatient procedure involves and next steps

The appointment itself is straightforward: ChondroFiller injection is delivered as an outpatient procedure under real-time ultrasound guidance. There is no theatre booking, no general anaesthetic, and no overnight admission. The image-guided approach allows the clinician to confirm accurate needle placement within the talar defect before the collagen gel is deposited and begins to polymerise in situ.

Aftercare involves a structured return-to-loading plan — not because the injection is extensive, but because the period between injection and stable defect filling is when the repair environment is most sensitive. Patients typically progress through an agreed sequence of restricted weight-bearing, graduated activity, and monitored return to sport, with specific milestones set according to defect size and individual response. Return to higher-impact activity is not immediate.

Follow-up includes imaging review — usually MRI — to assess scaffold integration and repair tissue quality at agreed intervals over the first year, alongside symptom review appointments.

Assessment at London Cartilage Clinic, Harley Street, establishes whether this pathway is appropriate by reviewing lesion grade, defect dimensions, and the health of the surrounding joint before any treatment decision is made. To arrange an assessment, visit londoncartilage.com.

1. [1] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
2. [2] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
3. [3] Autologous bone graft and periosteal patch for large and recurrent talar osteochondral defect. (2025). https://doi.org/10.1016/j.jcot.2025.103132 https://doi.org/10.1016/j.jcot.2025.103132
4. [4] Osteochondritis dissecans. https://en.wikipedia.org/?curid=3762029 https://en.wikipedia.org/?curid=3762029
5. [5] Articular cartilage repair. https://en.wikipedia.org/?curid=19042351 https://en.wikipedia.org/?curid=19042351
6. [6] Controlled, randomized multicenter study to compare ChondroFiller liquid with microfracturing for focal cartilage defects of the knee. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1